Job Title

This studentship covers tuition fees and a stipend for eligible students from the UK, RoI and EU only. In 2024, QUB established a new industry facing institute called the Future Medicines Institute. This is a £55M programme funded by Department of Economy NI and Industry partners, managed by the UKRI Strength in Places programme. This programme is a collaboration between regional Life and Health Sciences commercial and academic partners including Almac Discovery, Randox Laboratories, Almac Diagnostic Services, Diaceutics, Sonrai Analytics, Exploristics, Fusion Antibodies, HIRANI, Ulster University. As part of this exciting programme QUB are pleased to announce the establishment of a new doctoral training programme. Initially we are offering up to 10 studentships at QUB. There will also be studentships available in due course at Ulster University. The studentships are to help develop collaborative programmes of research between the partners and academic research at QUB. Furthermore, these projects are specifically designed to develop skills and training that are needed by the regional Life and Health Sciences sector. As part of the programme, the cohort of students will also become part of a new doctoral training programme in the Thomas J Moran Graduate School to develop bespoke skills for working with industry. The following projects are available:Data Integration and Platform Strategy for Precision Medicine at the Future Medicines Institute (FMI) Development of “beyond cysteine” covalent chemical probes and their application in next generation therapeutics Development of a novel screening platform for identification of drug targets in oesophageal cancer Development of B-Cell Cloning for the Isolation of High-Affinity Antibodies Development of Novel ADC linkers for Next Generation Therapeutics Development of novel phage display platforms for the development to diagnostic and therapeutic antibodies Engineering Protein Fate Through Next Generation Covalency Molecular Glue Modelling with AlphaFold3 New methodologies for the effective synthesis of novel molecular glues (MGs) using flow chemistries Next generation ADCs with enhanced anti-tumour efficacy: Development and profiling of novel multimeric ADC formats for improved payload delivery to cancer cells.#J-18808-Ljbffr